Related Experiment Video
Updated: Jan 31, 2026

Cortical Neurogenesis: Transitioning from Advances in the Laboratory to Cell-Based Therapies
Published on: July 19, 2007
Advances in Antiarrhythmic Drug Therapy: Potentials and Challenges
1Division of Cardiovascular Disease, Lankenau Medical Center, 100 E. Lancaster Avenue, Wynnewood, PA 19096, USA.
Abstract:
Antiarrhythmic drug therapy continues to be the cornerstone of management of both atrial and ventricular arrhythmias. Advances in the field were slowed by regulatory, scientific, clinical, and economic barriers. This review outlines the impediments to antiarrhythmic drug innovation and explores future therapies, including novel delivery platforms, atrial-selective drugs, and hybrid approaches. As the global prevalence of arrhythmias continues to rise, renewed investment in patient-centered, mechanism-driven pharmacotherapy is essential to complement existing procedural options and improve long-term outcomes.
Related Concept Videos
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Drug Therapy
Antianxiety Medications
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

